Needham analyst Serge Belanger maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $48.00. The company’s shares closed last Thursday at $24.09.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 2.6% and a 40.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Zogenix has an analyst consensus of Moderate Buy, with a price target consensus of $48.33, implying a 109.3% upside from current levels. In a report issued on July 24, Mizuho Securities also maintained a Buy rating on the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $57.22 and a one-year low of $16.65. Currently, Zogenix has an average volume of 985K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZGNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
Read More on ZGNX:
